Table 3.

Clinical trials examining smoothened antagonists combined FDA approved drugs

Smo Antagonist	Therapy (Target)	Cancer	Identifier
Vismodegib	Ribavirin±decitabine	AML	NCT02073838
Vismodegib	Erlotinib (EGFR)±gemcitabine	Pancreatic	NCT00878163
Vismodegib	Cisplatin+etoposide	SCLC	NCT00887159
Vismodegib	Sirolimus (mTOR)	Pancreatic	NCT01537107
Vismodegib	Pembrolizumab (PD-1)	BCC	NCT02690948
Vismodegib	Temozolomide	Medulloblastoma	NCT01601184
Vismodegib	Nivolumab (PD-1)	BCNS	NCT03767439
Sonidegib	Ribociclib	Brain	NCT03434262
Sonidegib	Azacitidine+decitabine	Leukemia	NCT02129101
Sonidegib	Fluorouracil+leucovorin+oxaliplatin+irinotecan	Pancreatic	NCT01485744
Sonidegib	Gemcitabine+Nab-paclitaxel	Pancreatic	NCT02358161
Sonidegib	Docetaxel+prednisone	Prostate	NCT02182622
Sonidegib	Lenalidomide	MM	NCT02086552
Sonidegib	Nilotinib (tyrosine kinase)	CML	NCT01456676
Sonidegib	Etoposide+cisplatin	SCLC	NCT01579929
Sonidegib	Everolimus (mTOR kinase)	Esophageal	NCT02138929
Sonidegib	Gemcitabine	Pancreatic	NCT01487785
Sonidegib	Docetaxel	Breast	NCT02027376
Sonidegib	Bortezomib	MM	NCT02254551
Sonidegib	Gemcitabine+Nab-paclitaxel	Pancreatic	NCT01431794
Sonidegib	Paclitaxel	Ovarian	NCT02195973
Saridegib	Gemcitabine	Pancreatic	NCT01130142
Glasdegib	Cytarabine+daunorubicin+decitabine	AML	NCT01546038
Glasdegib	Azacitidine	AML	NCT02367456
BMS-833923	Dasatinib	CML	NCT01357655
BMS-833923	Cisplatin+capecitabine	Gastric/Esophageal	NCT00909402
BMS-833923	Carboplatin+etoposide	SCLC	NCT00927875
BMS-833923	Dasatinib	CML	NCT01218477
Taladegib	Paclitaxel+carboplatin+radiation	Esophageal	NCT02530437

Abbreviations: AML, acute myeloid leukemia; EGFR, epidermal growth factor receptor; SCLC, small cell lung cancer; BCNS, basal cell Nevus syndrome; MM, multiple myeloma; CML, chronic myeloid leukemia